Industrial-Scale Downstream Purification Of Bacteriophages — ‘Clarification’ And ‘Ultrafiltration’ Section
Bacteriophages, also known as phages, are viruses that infect bacteria. A phage cannot survive on its own; it must parasitize a host bacterium to reproduce, ultimately causing the bacterium to lyse. Because of their unique properties, phages can be used clinically for bacterial identification and typing, as well as for the treatment of certain refractory bacterial infections.
This is a schematic diagram of a bacteriophage structure (image source: the internet).
It is estimated that plant diseases cause more than 30% of global crop yield losses each year. Among various pathogens, bacterial diseases are particularly difficult to control. Traditional control methods mainly rely on antibiotics and copper-based agents. However, the overuse of antibiotics has led to increasingly severe antimicrobial resistance, while the long-term use of copper compounds results in environmental accumulation, posing health risks to humans and animals.
Because bacteriophages have high specificity, they can selectively kill pathogenic bacteria without harming beneficial microbes or other host cells. Therefore, phages can serve as alternatives to antibiotics and copper-based agents. Through phage therapy, pathogens can be effectively eliminated while reducing the use of antibiotics and copper compounds.
With continuous scientific and technological advances and deeper research into bacteriophages, the prospects for using phages to treat superbugs are becoming increasingly promising. In the future, phage therapy is expected to become one of the key solutions to antibiotic resistance. Through ongoing research and exploration, phage therapy may emerge as a major force in the field of antimicrobial treatment, making greater contributions to human health.
However, to safely and effectively administer bacteriophages to the human body-especially via intravenous (IV) injection-one major challenge remains: how to obtain ultra-pure phage preparations.
Phage lysate is a complex mixture that, in addition to the target phages, contains major impurities such as: host bacteria and their fragments, genomic DNA, and host proteins (host-related impurities); endotoxins such as lipopolysaccharides (LPS) (process-related impurities); and product-related impurities including empty capsids and broken tails.
Therefore, the goal of purification is not only to achieve a high phage titer but also to reduce impurities-particularly endotoxins, host DNA, and proteins-to extremely low levels as specified by pharmacopeia standards.
A robust and scalable phage purification process generally follows the common principles of downstream processing and can be divided into the following logical steps:
Downstream Purification Process of Bacteriophages
Clarification – Removal of Macroscopic Impurities
At the initial stage of bacteriophage purification, the primary goal of the clarification step is to efficiently remove intact bacterial cells and large cellular debris from the crude lysate. The core purpose of this step is to provide a clean feed for downstream chromatography columns or membrane separation units, minimizing the load of solid particulates. This effectively prevents clogging in subsequent purification units, ensuring stable operation and high process efficiency throughout the purification workflow.
In traditional bacteriophage downstream processes, clarification typically relies on low-speed centrifugation combined with multi-stage depth filtration-commonly passing sequentially through 0.8μm, 0.45μm, and 0.22μm filters-to effectively remove host cell debris and impurities. Although mature and reliable, this approach involves multiple steps, is time-consuming, and requires repeated material transfers, leaving room for optimization in overall yield and efficiency.
Replacing the multi-stage depth filtration with a microfiltration capsule can significantly simplify and intensify the process. Specifically, after removing most cell debris through low-speed centrifugation, the lysate can be directly processed by tangential flow filtration (TFF) using microfiltration capsules with defined pore sizes (0.45μm or 0.22μm). This enables the fine removal of particulate impurities and efficient permeation of target phages in a single step, effectively integrating the traditional three filtration stages into one.
This innovation not only greatly reduces operation time and manual handling but also minimizes sample loss and contamination risk caused by multiple filtration steps, thereby improving overall phage recovery. Meanwhile, the tangential flow operation mitigates membrane fouling, enhances throughput, and strengthens process robustness.
Therefore, adopting an integrated clarification strategy combining low-speed centrifugation and microfiltration capsules represents an effective approach to improve the efficiency and cost-effectiveness of large-scale bacteriophage production. Guidling Technology's microfiltration capsules can typically reduce feed turbidity to below 20 NTU, fully meeting the requirements of subsequent ultrafiltration and chromatography steps.
Capture and Concentration – Primary Purification and Volume Reduction
During the capture and concentration stage of bacteriophage purification, the main objective is to efficiently recover phages from large volumes of clarified lysate while simultaneously achieving primary product concentration and buffer exchange. This step primarily relies on Tangential Flow Filtration (TFF) technology.
The principle of TFF lies in the use of ultrafiltration membranes with specific molecular weight cut-offs (typically 100 or 300kDa). Small molecular impurities such as residual culture media components, metabolites, and small proteins selectively pass through the membrane pores, while phages are retained in the retentate due to size exclusion effects, enabling their effective separation and enrichment.
Within a TFF system, ultrafiltration mode is employed to achieve volume concentration, while switching to diafiltration mode allows buffer exchange, thus creating suitable physicochemical conditions for subsequent steps such as enzymatic treatment.
This technology offers the combined advantages of high processing efficiency and excellent scalability, making it ideal for large-scale production. According to GuidlingTechnology, the ultrafiltration capsules typically achieve a phage recovery rate of 90–95%, depending on the specific material being processed.
Deep Purification – Targeted Removal of Critical Impurities
In bacteriophage purification, deep purification is the key step that determines the final product quality. Its primary goal is the specific removal of critical impurities, such as endotoxins. Traditional CsCl density gradient centrifugation-due to its toxicity and lack of scalability-has been eliminated from industrial processes. Current approaches focus on chromatography-based technologies, with innovative integration of enzyme pretreatment.
An advanced strategy combining anion exchange chromatography (AEC) with alkaline phosphatase (AP) pretreatment has been developed. Both phages and lipopolysaccharides (LPS) carry negative charges, leading to competition for binding sites in conventional AEC processes and causing co-elution that reduces purification efficiency. By introducing AP pretreatment before AEC loading, the enzyme specifically removes phosphate groups from the lipid A and core polysaccharide regions of LPS molecules, significantly reducing their net negative charge. This effectively weakens their affinity for the anion exchange medium.
Experimental data show that treating the sample with 20 U/mL AP followed by purification using quaternary amine (Q) ligand membrane adsorbers or monolithic columns can achieve up to 98.8% endotoxin removal, while maintaining excellent phage recovery rates. This approach successfully resolves the long-standing issue of endotoxin co-adsorption during phage purification
Polishing – Final Refinement and Formulation
In the final polishing stage of bacteriophage purification, the main objective is to achieve ultimate purity and formulation readiness. This includes removing trace residual impurities, eliminating additives introduced during the process (such as alkaline phosphatase), and completely exchanging the product into a formulation-compatible buffer system.
This is typically accomplished through secondary diafiltration, a proven and efficient method that enables both deep removal of small-molecule contaminants and thorough buffer exchange.
To further enhance product purity, hydrogen-bond interaction chromatography or mixed-mode chromatography (MMC) can be introduced as a final polishing step. These techniques utilize multidimensional separation mechanisms to remove trace components with physicochemical properties similar to those of the target phage. The result is a highly purified bacteriophage active pharmaceutical ingredient (API) that meets the stringent quality standards required for injection-grade formulations.
By selecting a combination of microfiltration and ultrafiltration membrane modules with a membrane area of 1 m², the estimated maximum volume of bacteriophage that can be processed reaches up to 100 L. The microfiltration material flux is approximately 20–50 LMH, and the ultrafiltration material flux is approximately 15–30 LMH. Compared with traditional processing methods, this approach can efficiently meet the process requirements for both clarification and ultrafiltration.
References:
Saavedra et al., Scalable purification of bacteriophage preparations (2025)
Lapras et al., Rationalisation of the purification process for a phage active pharmaceutical ingredient (2024)
